Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: An evidence-based comparison

Drugs and Aging

Volumn 20, Issue 11, 2003, Pages 847-855

  Inzelberg, Rivka ^a,b   Schechtman, Edna ^c   Nisipeanu, Puiu ^a  

^a HILLEL YAFFE MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PRAMIPEXOLE; ROPINIROLE;

ACUTE DISEASE; ANXIETY DISORDER; CLINICAL TRIAL; DEPRESSION; DISEASE COURSE; DRUG CHOICE; DRUG EFFICACY; DRUG TOLERABILITY; DYSKINESIA; EDEMA; HALLUCINATION; HEADACHE; HUMAN; HYPOTENSION; MONOTHERAPY; NAUSEA; PARKINSON DISEASE; PATIENT ATTITUDE; PRIORITY JOURNAL; REVIEW; RISK; SCORING SYSTEM; SLEEP DISORDER; SOMNOLENCE; VERTIGO;

AGE OF ONSET; BENZOTHIAZOLES; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; ERGOLINES; EVIDENCE-BASED MEDICINE; HUMANS; INDOLES; LEVODOPA; PARKINSON DISEASE; THIAZOLES;

EID: 0141649537     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200320110-00006     Document Type: Review

References (25)

1. Olanow CW, Watts R, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. Neurology 2001; 56 Suppl. 5: S1-S88
2. Shrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease: a community-based study. Brain 2000; 123: 2297-305
3. Rascol O, Goetz C, Koller W, et al. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 2002; 359: 1589-98
4. Ramaker C, Van Hilten JJ. Bromocriptine versus levodopa in early Parkinson's disease. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 3: Oxford: Update Software, 2000: CD002258
5. Parkinson's Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. BMJ 1993; 307: 469-72
6. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Drugs 1998; 55, Suppl. 1: 23-30
7. Hundemer HP, Lledo A, Van Laar T, et al. The safety of pergolide monotherapy in early-stage Parkinson's disease: one-year interim analysis of a 3-year double-blind, randomized study of pergolide versus levodopa [abstract]. Mov Disord 2000; 15 Suppl. 3: 115
8. Lledo A, Hundemer HP, Van Laar T, et al. Long term efficacy of pergolide monotherapy in early-stage Parkinson's disease (PD): one-year interim analysis of a 3-year double-blind, randomized study of pergolide versus levodopa [abstract]. Mov Disord 2000; 15 Suppl. 3: 126
9. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson's disease. JAMA 2000; 284: 1931-8
10. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000; 342: 1484-91
11. Albin RL, Frey KA. Initial agonist treatment of Parkinson disease. Neurology 2003; 60: 390-4
12. Chase T, Baronti F, Fabbrini G, et al. Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology 1989; 114: 1429-40
13. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001; 16: 448-58
14. Parkinson Study Group. Dopamine transporter brain imaging to ascertain the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287: 1653-61
15. Whone AL, Remy P, Davis MR, et al. The REAL-PET study: slower progression in early Parkinson's disease treated with ropinirole compared with 1-dopa. Neurology 2002; 8: A82-3
16. Ahlskog JE. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology 2003; 60: 381-9
17. Fahn S, Elton R. Unified Parkinson's disease Rating Scale Development Committee. Unified Parkinson's disease Rating Scale. In: Fahn S, Marsden CD, Calne D, editors. Recent developments in Parkinson's disease. New York: MacMillan, 1987: 153-63
18. Schechtman E. Odds ratio, relative risk, absolute risk reduction, and the number needed to treat: which one should we use? Value Health 2002; 5: 431-6
19. Hedges LV, Olkin I. Statistical methods for meta-analysis. California: Academic Press Inc, 1985
20. Agresti A. Categorical data analysis. New York: Wiley, 1990
21. Song F, Altman DG, Glenny A-M, et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003; 326: 472-6
22. Inzelberg R, Carasso RL, Schechtman E, et al. A comparison of dopamine agonists and catechol-O-methyltransferase inhibitots in Parkinson's disease. Clin Neuropharmacol 2000; 23: 262-6
23. Rascol O. Ropinirole as compared with levodopa in Parkinson's disease [letter]. N Engl J Med 2000; 343: 885
24. Shenker N, Gentleman JF. On judging the significance of differences by examining the overlap between confidence intervals. Am Stat 2001; 55: 182-6
25. Miyasaki JM, Martin W, Suchowersky O, et al. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review. Neurology 2002; 58: 11-7